Ferro-Bob and Linezolid

• Generic Name: ferrous sulfate
• Dosage Forms: n.a.
• Other Brand Names: Feosol, Fer-Gen-Sol, Fer-in-Sol, Fer-Iron, FeroSul, Ferra TD. Caps, Ferro-Bob, Ferrousal, Lydia E. Pinkham, MyKidz Iron 10, Slow Fe, Slow Release Iron, Fe Caps, Feratab, Fer Iron, Fer-in-Sol, Ferra-TD

Ferro-Bob is a type of iron. You normally get iron from the foods you eat. In your body, iron becomes a part of your hemoglobin (HEEM o glo bin) and myoglobin (MY o glo bin). Hemoglobin carries oxygen through your blood to tissues and organs. Myoglobin helps your muscle cells store oxygen.

Ferro-Bob is used to treat iron deficiency anemia (a lack of red blood cells caused by having too little iron in the body).

Ferro-Bob may also be used for purposes not listed in this medication guide.

• Generic Name: linezolid
• Dosage Forms: n.a.
• Other Brand Names: Zyvox

Treatment of community-acquired pneumonia (CAP), including infections associated with concurrent bacteremia, caused by susceptible Streptococcus pneumoniae.

Treatment of CAP caused by susceptible Staphylococcus aureus (methicillin-susceptible [oxacillin-susceptible] strains only). Also recommended for treatment of CAP caused by methicillin-resistant S. aureus (MRSA; also known as oxacillin-resistant S. aureus or ORSA).

Treatment of nosocomial pneumonia caused by susceptible S. aureus (including MRSA) or S. pneumoniae.

Not indicated for treatment of respiratory tract infections caused by gram-negative bacteria. It is imperative that an anti-infective active against gram-negative bacteria be used concomitantly if documented or presumed pathogens include gram-negative bacteria.

Skin and Skin Structure Infections

Treatment of uncomplicated skin and skin structure infections caused by susceptible S. aureus (methicillin-susceptible [oxacillin-susceptible] strains only) or S. pyogenes (group A β-hemolytic streptococci, GAS).

Treatment of complicated skin and skin structure infections (including diabetic foot infections), without concurrent osteomyelitis, caused by susceptible S. aureus (including MRSA), S. pyogenes, or S. agalactiae (group B streptococci, GBS).

Not evaluated for use in the treatment of decubitus ulcers.

Not indicated for treatment of skin and skin structure infections caused by gram-negative bacteria. It is imperative that an anti-infective active against gram-negative bacteria be used concomitantly if the documented or presumed pathogens include gram-negative bacteria.

Vancomycin-resistant Enterococcus faecium Infections

Treatment of infections caused by susceptible vancomycin-resistant Enterococcus faecium, including infections associated with concurrent bacteremia.

Has been used for treatment of native valve or prosthetic valve infective endocarditis caused by vancomycin-resistant or multidrug-resistant E. faecium. AHA recommends that patients with infective endocarditis attributable to enterococci resistant to penicillins, aminoglycosides, and vancomycin be managed by a team of specialists in infectious disease, cardiology, cardiovascular surgery, clinical pharmacy, and, if necessary, pediatrics.

CNS Infections

Has been recommended as an alternative to vancomycin for treatment of CNS infections caused by MRSA (e.g., meningitis, brain abscess, subdural empyema, spinal epidural abscess).